Scholars@Duke
Katherine Cheng

Katherine Cheng

Assistant Professor of Radiology
Radiology, Cardiothoracic Imaging

Selected Publications

Imaging of Smoking and Vaping Related Diffuse Lung Injury.

Journal Article Radiol Clin North Am · November 2022 Lung injury associated with smoking tobacco or other substances results in a variety of clinical presentations and imaging patterns, depending on mechanism of injury and substance inhaled. Patients may present in the acute setting, as in the case of acute ... Full text Link to item Cite

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Journal Article Cancer Res · June 1, 2014 Although several groups have demonstrated that concomitant use of MEK and phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor regressions in mouse models of KRAS-mutant non-small cell lung cancer (NSCLC), ongoing clinical tri ... Full text Link to item Cite

Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.

Journal Article Clin Cancer Res · March 1, 2014 PURPOSE: To extend the results of a phase III trial in patients with non-small cell lung cancer with adenocarcinomas harboring EML4-ALK fusion. EXPERIMENTAL DESIGN: We conducted a co-clinical trial in a mouse model comparing the ALK inhibitor crizotinib to ... Full text Link to item Cite

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Journal Article Clin Cancer Res · November 15, 2013 PURPOSE: Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth, invasion, and drug resistance. Murine genetics has established both the centrality of somatic alterat ... Full text Link to item Cite

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Journal Article Cancer Cell · January 14, 2013 KRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy to identify genes that, when inhibited, cooperate with MEK inhibitors to effectively treat KRAS ... Full text Link to item Cite

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.

Journal Article Cancer Res · July 1, 2012 Tyrosine kinase inhibitors (TKI) that target the EGF receptor (EGFR) are effective in most non-small cell lung carcinoma (NSCLC) patients whose tumors harbor activating EGFR kinase domain mutations. Unfortunately, acquired resistance eventually emerges in ... Full text Link to item Cite

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Journal Article Nature · March 18, 2012 Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers. Although most patients with lung cancer are stratified according to a single oncogenic driver, cancers harbouring identical activating genetic mutations ... Full text Link to item Cite

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Journal Article Nat Med · June 26, 2011 Cells that are deficient in homologous recombination, such as those that lack functional breast cancer-associated 1 (BRCA1) or BRCA2, are hypersensitive to inhibition of poly(ADP-ribose) polymerase (PARP). However, BRCA-deficient tumors represent only a sm ... Full text Link to item Cite